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INTRODUCTION
Endogenous guanosine and guanine can be modified in the 8-position to yield a number of endogenous 8-substituted guanosines and guanines including 8-nitroguanosine (Akaike et al., 2003) , 8-aminoguanosine (Sodum et al., 1993) , 8-hydroxyguanosine (Park et al., 1992) , 8-nitroguanine (Ohshima et al., 2006) , 8-hydroxyguanine (Fraga et al., 1990 ) and 8-hydroxy-2'-deoxyguanosine (Lam et al., 2012) . Until recently, nothing was known concerning the effects of these naturally-occurring 8-substituted guanosine and guanine compounds on the cardiovascular system or kidneys.
To address this knowledge gap, we systematically examined a series of 8-substituted guanosines and guanines on the cardiovascular system and kidneys in rats (Jackson et al., 2016) .
In particular, we examined the renal effects in vivo of intravenous administration of guanosine, guanine, 8-nitroguanosine, 8-nitroguanine, 8-hydroxyguanosine, 8-hydroxyguanine, 8-hydroxy-2'-deoxyguanosine, 8-aminoguanosine and 8-aminoguanine. We observed that 8-aminoguanosine and 8-aminoguanine produced marked diuresis, natriuresis, and glucosuria, and reduced potassium excretion (Jackson et al., 2016) . Moreover, long-term oral treatment of rats with 8-aminoguanosine and 8-aminoguanine attenuated the development of deoxycorticosterone/salt-induced hypertension (Jackson et al., 2016) .
In the systemic circulation, exogenous 8-aminoguanosine can be converted to 8-aminoguanine by purine nucleoside phosphorylase (PNPase) (Osborne and Barton, 1986) .
Therefore, it is conceivable that 8-aminoguanosine does not act directly on the kidneys to induce the aforementioned effects but rather functions as a "pro-drug" (if exogenous) or a "prohormone" (if endogenous). The goal of the present study was to test this hypothesis.
METHODS

Materials. 8-Aminoguanosine and 8-aminoguanine were purchased from Toronto
Research Chemicals (Toronto, Ontario, Canada).
Animals. This study employed male Sprague-Dawley rats (Charles River; Wilmington, MA) that were approximately 16 weeks of age. The Institutional Animal Care and Use
Committee approved all procedures. The investigation conforms to National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Protocol 1. After inducing anesthetized with Inactin (90 mg/kg, i.p.), each rat was positioned on an isothermal pad. A thermometer probe was inserted into the rectum, and the rat's body temperature was continuously monitored and maintained at 37ºC by adjusting the distance of a heat lamp from the animal's body. Using a polyethylene (PE)-240 tubing, the trachea was cannulated to aid respiration. Next, a PE-50 cannula was inserted into the carotid artery and connected to a digital blood pressure analyzer (Micro-Med, Inc., Louisville, KY) for continuous measurement of mean arterial blood pressure (MABP) and heart rate (HR). A PE-50 cannula was placed in the jugular vein, and an infusion of 0.9 % saline (50 l/min) was begun.
Finally, a PE-10 cannula was inserted into the left ureter for timed collections of urine. After a stabilization period of approximately one hour, urine was collected for 30 minutes while MABP and HR were time-averaged (Period 1: 0-30 minutes into protocol). Next, 8-aminoguanosine (33.5 µmoles/kg; 1 ml/kg) or 8-aminoguanine (33.5 µmoles/kg; 1 ml/kg) or vehicle (0.9% saline containing 0.03 N HCl; 1 ml/kg) was administered intravenously as a bolus. The dose was selected based on our previous work (Jackson et al., 2016) . Rats were randomized to treatment groups, and rats in each group received only one treatment. Creatinine clearance was calculated as an estimate of glomerular filtration rate (GFR).
Protocol 2. Rats were prepared in a similar fashion to that described in Protocol 1, but with modifications. Specifically, microdialysis probes were inserted into the cortex and medulla of the right kidney and were perfused at 2 ul/min with 0.9 % saline. The microdialysis probes used in this protocol were from Bioanalytical Systems (West Lafayette, IN; CMA/20 microdialysis probe 4 mm; outer diameter of 0.5 mm; 20,000 dalton membrane cut-off). After initiating the probe perfusions, the infusion rate of 0.9% saline via the jugular vein was reduced to 25 l/min after to avoid volume overload. At this point in the protocol, the rats were allowed to stabilize for two hours in order for the kidney to recover from the trauma induced by the probe insertions.
Next, microdialysate from the renal cortex and medulla and urine were collected for 30 minutes, and MABP and HR were time averaged during this first (basal) period. Rats then were randomized to receive 8-aminoguanosine or 8-aminoguanine or vehicle at the dose and manner described for Protocol 1. Ten minutes after treatments, microdialysate from the renal cortex and JPET #243758 medulla and urine were again collected for 30 minutes, and MABP and HR were time averaged during this treatment period. After 15 minutes, this procedure was repeated one more time. 8-Aminoguanosine and 8-aminoguanine were measured in urine and microdialysate using ultraperformance liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described below.
Protocol 3. Rats were prepared in a similar fashion to that described in Protocol 1, but with a few additions. In this regard, PE-10 cannulas were inserted into both the left and right ureters for urine collection from both kidneys simultaneously. Also, a 1 mm transit-time flow probe was positioned on left renal artery and connected to a flowmeter (model T-206, Transonic
Systems, Inc., Ithaca, NY) for continuous measurement of renal blood flow (RBF). Since placing a flow probe on left renal artery partially denervates the kidney, to ensure that both kidneys were under similar conditions, both kidneys were denervated. Finally, a 30-gauge needle was inserted into the lumen of the left renal artery and an infusion of 0.9% saline at 50 l/min was initiated. The infusion rate of 0.9% saline via the jugular vein was reduced to 25 l/min to avoid volume overload.
After a stabilization period of one hour, urine was collected from both kidneys for 15 minutes (for urine volume, sodium, potassium, and glucose) and MABP and HR were time averaged during this period. Also, RBF was recorded at 5, 10, and 15 minutes into the 15-minute urine collection period and averaged. Next, rats received an infusion into the left renal artery of either 8-aminoguanine or 8-aminoguanosine (0.1 µmoles/kg/min at 50 l/min) or vehicle (also 50 l/min). Ten minutes later, urine was again collected for 15 minutes and all measurements were repeated. In rats receiving 8-aminoguanine or 8-aminoguanosine, the dose of these compounds was increased to 0.3 µmoles/kg/min. After 10 minutes, urine was again JPET #243758 collected for 15 minutes and all measurements were repeated. The procedure was repeated once more after increasing the dose of 8-aminoguanosine or 8-aminoguanine to 1 µmole/kg/min. Sodium, potassium, and glucose were measured in all urine samples as described in Protocol 1.
Assay for 8-Aminoguanosine and 8-Aminoguanine. Purines in urine and microdialysate were measured by LC-MS/MS using a method similar to that previously described by us (Jackson et al., 2009 ), but with modifications. In this regard, purines were separated by reversed-phase ultra-performance liquid chromatography (Waters UPLC BEH C18 column, 1.7 µm beads; 2.1 x 150 mm; Milford, MA) and quantified by selected reaction monitoring using a triple quadrupole mass spectrometer (TSQ Quantum-Ultra; ThermoFisher Scientific, San Jose, CA) with a heated electrospray ionization source. The mobile phase was a linear gradient flow rate (300 uL/min) of 1% acetic acid in water (pH, 3; mobile phase A) and 100% methanol (mobile phase B), and was delivered with a Waters Acquity ultra-performance liquid chromatographic system. The gradient (A/B) settings were: from 0 to 2 minutes, 99.6%/0.4%; from 2 to 3 minutes, to 98.0%/2.0%; from 3 to 4 minutes, to 85.0%/15.0%; from 4 to 6.5 minutes, to 99.6%/0.4%. The instrument parameters were: sample tray temperature, 10°C; column temperature, 50°C; ion spray voltage, 4.0 kilovolts; ion transfer tube temperature, 350°C; source vaporization temperature, 320°C; Q2 CID gas, argon at 1.5 mTorr; sheath gas, nitrogen at 60 psi; auxillary gas, nitrogen at 35 psi; Q1/Q3 width, 0.7/0.7 units full-width half-maximum; scan width, 0.6 units; scan time, 0.01 seconds. For 8-aminoguanosine, the parent ion was m/z = 299, the daughter ion was m/z = 167, and the retention time was 3.64 min. This article has not been copyedited and formatted. The final version may differ from this version.
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RESULTS
Protocol 1:
To confirm the dosing paradigm, we examined in a head-to-head study (with randomization of treatment groups) the effects of an intravenous bolus of vehicle (control group),
8-aminoguanosine (33.5 µmoles/kg), and 8-aminoguanine (33.5 µmoles/kg) in anesthetized rats.
As shown in Figures (Fraga et al., 1990 ) and 8-hydroxy-2'-deoxyguanosine (Lam et al., 2012) . Because the cardiovascular and renal effects of these compounds had not been reported, recently we systematically examined in vivo the cardiovascular and renal effects of several naturally-occurring 8-substituted guanosine and guanine derivatives (Jackson et al., 2016) . In this regard, we observed that intravenous administration of 8-nitroguanine, 8-hydroxyguanosine,
8-hydroxyguanine, 8-aminoguanosine, and 8-aminoguanine caused diuresis and natriuresis; and of these compounds, 8-aminoguanosine and 8-aminoguanine were particularly efficacious (Jackson et al., 2016) . Both markedly increased urine volume and increased the urinary excretion of sodium and glucose, while suppressing urinary potassium excretion (Jackson et al., 2016) . Because of the unique qualities of 8-aminoguanosine and 8-aminoguanine, we are currently investigating more fully the pharmacology of these two compounds.
Because exogenous 8-aminoguanosine can be converted to 8-aminoguanine by purine nucleoside phosphorylase (Osborne and Barton, 1986) , we entertained the hypothesis that 8-aminoguanosine might be a "pro-drug" or "pro-hormone" (depending upon whether the source of the 8-aminoguanosine is exogenous or endogenous). That is to say, we considered the concept that the effects of 8-aminoguanosine on the kidneys are not direct but are mediated by its metabolism to 8-aminoguanine.
To address this hypothesis, we first compared head-to-head the renal effects of intravenously administered 8-aminoguanosine and 8-aminoguanine. Both compounds increased To further explore our hypothesis, we next administered low doses of 8-aminoguanosine and 8-aminoguanine directly into the left renal artery while monitoring the excretion of urine, sodium, potassium, and glucose from both the ipsilateral (treated) and contralateral (control) kidneys. Our logic here was that if 8-aminoguanosine is an 8-aminoguanine prodrug and if the conversion of arterial 8-aminoguanosine to 8-aminoguanine occurs largely in the systemic circulation, then administration of 8-aminoguanosine into the renal artery should be inactive whereas administration of matched doses of 8-aminoguanine should induce diuresis and natriuresis.
Consistent with our hypothesis, intrarenal artery infusions of 8-aminoguanosine did not affect urine volume or the urinary output of sodium or glucose at any of the doses tested. In contrast, at all doses tested, administration of 8-aminoguanine into the renal artery markedly increased urine excretion, sodium excretion, and glucose excretion in the infused kidney. Yet, in the non-infused kidney only the highest dose of 8-aminoguanine affected these parameters, and even then only slightly. These results are highly consistent with the concept that 8-aminoguanine has direct intrarenal actions to cause diuresis, natriuresis, and glucosuria; whereas 8-aminoguanosine does not and requires metabolism to 8-aminoguanine.
Interestingly, 8-aminoguanine decreased potassium excretion when administered intravenously, but not when administered directly into the renal artery. This is likely related to the fact that the intrarenal doses of 8-aminoguanine had to be low because of poor solubility. We observed that higher concentrations of 8-aminoguanine precipitated and clogged the needle inserted into the renal artery; so low doses were used in these experiments. At the doses employed, likely the increased presentation of sodium to the distal nephron offset the tendency for 8-aminoguanine to decrease potassium excretion such that the net effect of intrarenal 8-aminoguanine was "potassium-sparing", but did not decrease potassium excretion overall.
A very important finding is that despite the fact that intrarenal artery administration of 8-aminoguanosine did not affect urine volume or sodium or glucose excretion, intrarenal artery infusions of 8-aminoguanosine did significantly reduce potassium excretion by the ipsilateral kidney. This suggests that 8-aminoguanosine directly induces antikaliuresis and that this aspect of the pharmacology of 8-aminoguanosine does not require conversion to 8-aminoguanine.
Unlike 8-aminoguanine, intrarenal artery infusions of 8-aminoguanosine did not increase sodium excretion and therefore the antikaliuretic effects of 8-aminoguanosine were observable (i.e., were not masked by increased sodium delivery to the distal nephron). Taken together, these findings suggest two very distinct mechanisms of action of 8-aminoguanine/8-aminoguanosine. One mechanism causes diuresis, natriuresis, and glucosuria and is mediated directly by 8-aminoguanine and indirectly by 8-aminoguanosine; and a separate mechanism causes antikaliuresis and is mediated directly by both 8-aminoguanine and 8-aminoguanosine. This hypothesis must be further tested by experiments designed to elucidate the molecular mechanisms underlying the effects of 8-aminoguanine and 8-aminoguanosine on the renal nephron.
Both 8-aminoguanosine and 8-aminoguanine inhibit PNPase. However, 8-aminoguanine is at least 10-fold more potent than 8-aminoguanosine in this regard (Kazmers et al., 1981;  This article has not been copyedited and formatted. The final version may differ from this version. JPET #243758 Gilbertsen and Dong, 1985) . Therefore, the fact that 8-aminoguanosine is an 8-aminoguanine prodrug is consistent with the hypothesis that the diuretic/natriuretic/glucosuric activity of these compounds is related to 8-aminoguanine-induced inhibition of renal PNPase. We are currently testing this hypothesis.
The present study provides strong evidence that the diuretic, natriuretic, and glucosuric activity of 8-aminoguanosine is due to its conversion to 8-aminoguanine. Since intrarenal artery administration of 8-aminoguanosine does not induce diuresis/natriuresis/glucosuria whereas intravenous administration does, our results suggest that arterial 8-aminoguanosine is processed to 8-aminoguanine mostly in the systemic circulation. It is important to point out that this does not preclude the possibility that endogenous 8-aminoguanosine produced within some nonvascular compartments within the kidney may be metabolized to 8-aminoguanine locally in the kidney and thus exert effects on nephron function. Additional experiments are required to test this hypothesis.
Likely, the metabolism of 8-aminoguanosine to 8-aminoguanine occurs mostly in the liver and red blood cells because: 1) both hepatocytes (Brass and Mody, 1995) and red blood cells (Back et al., 1992) An important issue is the clinical relevance of 8-aminoguanosine and 8-aminoguanine.
Previously we published that both compounds attenuated the development of hypertension in uninephrectomized rats treated with deoxycorticosterone and provided 1% NaCl as drinking water (Jackson et al., 2016) . In unpublished, preliminary experiments, we have observed antihypertensive effects of these compounds in Dahl SS rats on a high salt diet, in ZDSD rats with the metabolic syndrome, and in spontaneously hypertensive rats. We have also observed that both 8-aminoguanosine and 8-aminoguanine extended the life span of Dahl SS rats on a high salt diet, apparently by preventing strokes. In ZDSD rats, we found that 8-aminoguanine decreased HbA1C levels. Finally, we have evidence of beneficial effects of these compounds in pulmonary hypertension and sickle cell disease. Although these studies are ongoing, we believe that 8-aminoguanosine and/or 8-aminoguanine may have significant utility in the management of renal and cardiovascular diseases.
In conclusion, the present study: 1) confirms the diuretic, natriuretic, glucosuric, and antikaliuretic effects of systemically administered 8-aminoguanosine and 8-aminoguanine; 2) shows that the renal effects of these compounds are not due to inhibition of aldosterone release; 3)
demonstrates that with respect to inducing diuresis, natriuresis, and glucosuria, 8-aminoguanosine is an 8-aminoguanine prodrug; and 4) suggests that the mechanism by which 8-aminoguanosine and 8-aminoguanine cause anti-kaliuresis is distinct from the mechanism by which they induce diuresis, natriuresis, and glucosuria. Further studies are warrantied to investigate the pharmacology and clinical utility of 8-aminoguanosine and 8-aminoguanine and to explore the physiological significance of endogenous 8-aminoguanosine and 8-aminoguanine.
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